Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020065113 - IMIPRAMINE FOR USE AS AN INHIBITOR OF FASCIN1 OVEREXPRESSION

Publication Number WO/2020/065113
Publication Date 02.04.2020
International Application No. PCT/ES2019/070631
International Filing Date 22.09.2019
IPC
A61K 45/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
A61K 31/517 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
517ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/55 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
CPC
A61K 31/55
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
Applicants
  • FUNDACION UNIVERSITARIA SAN ANTONIO [ES]/[ES]
  • FUNDACION PARA LA FORMACIÓN E INVESTIGACIÓN SANITARIAS [ES]/[ES]
  • UNIVERSIDAD DE GRANADA [ES]/[ES]
Inventors
  • CONESA ZAMORA, Pablo
  • PEREZ SANCHEZ, Horacio
  • LUQUE FERNÁNDEZ, Irene
  • MONTORO GARCÍA, Silvia
  • ALBURQUERQUE GONZALEZ, Begoña
  • CAMPIONI RODRIGUES, Priscila
  • GARCÍA SOLANO, José
  • BERNABÉ GARCÍA, Angel
  • NICOLÁS VILLAESCUSA, Francisco José
  • BERNABÉ GARCÍA, Manuel
  • CAYUELA FUENTES, Maria Luisa
  • RUIZ SANZ, Javier
  • MARTÍNEZ HERRERÍAS, Jose Cristobal
  • SALO, Tuula
Agents
  • DIAZ PACHECO, María Desamparados
Priority Data
18382696.528.09.2018EP
Publication Language Spanish (ES)
Filing Language Spanish (ES)
Designated States
Title
(EN) IMIPRAMINE FOR USE AS AN INHIBITOR OF FASCIN1 OVEREXPRESSION
(ES) IMIPRAMINA PARA USO COMO INHIBIDOR DE LA SOBREXPRESIÓN DE LA FASCINA 1
(FR) IMIPRAMINE DESTINÉE À ÊTRE UTILISÉE EN TANT QU'INHIBITEUR DE LA SUREXPRESSION DE LA FASCINE 1
Abstract
(EN)
The present invention refers to imipramine for use as an inhibitor of fascin1 overexpression. Preferably said overexpression of fascin1 is associated with cancer, and more preferably with colorectal cancer. The invention also relates to a method for the treatment of cancer mediated by fascin1 involving administering an effective amount of imipramine to a subject in need, and more preferably for colorectal cancer.
(ES)
La presente invención se refiere a imipramina para su uso como inhibidor de la sobreexpresión de la fascina 1, preferiblemente dicha sobreexpresión de la fascina 1 está asociada a cáncer, y más preferiblemente a cáncer colorrectal. También se refiere a un método para el tratamiento del cáncer mediado por fascina 1 que comprende administrar a un sujeto que así lo requiere, una cantidad efectiva de imipramina, y más preferiblemente para el cáncer colorrectal.
(FR)
La présente invention concerne une imipramine destinée à être utilisée en tant qu'inhibiteur de la surexpression de la fascine 1, de préférence ladite surexpression de la fascine 1 est associée au cancer et plus préférablement au cancer colorectal. L'invention se rapporte à une méthode de traitement du cancer médié par la fascine 1 qui comprend l'administration à un sujet qui en a besoin, d'une quantité efficace d'imipramine, et plus préférablement pour le cancer colorectal.
Also published as
Latest bibliographic data on file with the International Bureau